# Journal Pre-proof

Is S100B protein useful in the follow up of non-metastatic cutaneous melanoma patients? A real-world cohort study

L Martos-Cabrera B Hernández-Marín B C Nuñez-Arenas A Tejera-Vaquerizo P Rodríguez-Jiménez

Please cite this article as: Martos-Cabrera L, Hernández-Marín B, Nuñez-Arenas BC, Tejera-Vaquerizo A, Rodríguez-Jiménez P, Is S100B protein useful in the follow up of non-metastatic cutaneous melanoma patients? A real-world cohort study, *Actas dermosifiliograficas* (2024), doi: https://doi.org/10.1016/j.ad.2024.06.013

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Sección, Cartas científico clínicas

Is S100B protein useful in the follow up of non-metastatic cutaneous melanoma patients? A real-world cohort study

¿Es útil la proteína S100b en el seguimiento de pacientes con melanoma cutáneo no metastásico? Un estudio de cohortes en práctica clínica real.

L Martos-Cabrera1*, B Hernández-Marín2, B C Nuñez-Arenas3, A Tejera-Vaquerizo4,5, and P Rodríguez-Jiménez1*

1. **Names of institutions:**

1 Dermatology Department, Hospital Universitario de la Princesa (Madrid, Spain)
2 Oncology department. Hospital Universitario de la Princesa (Madrid, Spain)
3 Laboratory Department, Hospital Universitario de la Princesa (Madrid, Spain)
4 Cutaneous Oncology Unit. Hospital San Juan de Dios (Córdoba, Spain)
5 Instituto Dermatológico GlobalDerm. Palma del Río (Córdoba, Spain)

*Both authors share senior authorship.

Corresponding author: Luisa.Martos-Cabrera
E-mail address: marialuisa.martoscabrera@gmail.com

To the Editor,

Introduction

Malignant melanoma–one of the fastest-increasing types of cancer worldwide–poses significant challenges due to the long follow-up periods required for the patients. [1,2] The increasing incidence of melanoma exerts even more pressure to health care systems everywhere.[3] Although early detection of melanoma recurrence is beneficial, there is still no international consensus on the optimal surveillance and follow-up strategies for melanoma patients. Furthermore, these strategies vary considerably across different countries and medical centers. [3-5]

Many physicians across Europe, following clinical practice guidelines, such as those published by the European Society for Medical Oncology, routinely monitor serum levels of S100b protein in melanoma patients. [4,6,7] Elevated levels of S100b at diagnosis or increasing levels during follow-up have been associated with a higher risk of disease progression and poorer prognosis. [3,5,6] However, the predictive value of S100b for early detection of local or distant metastasis is somewhat limited. [4, 7]

The aim of this study is to establish the usefulness of S100b determination to detect melanoma recurrence in the real-world clinical practice.

Materials and Methods

We conducted a retrospective, observational cohort study at the Melanoma Unit of Hospital Universitario La Princesa (Madrid, Spain) a tertiary referral center for melanoma. The study included all consecutive adult melanoma patients monitored from January 2015 throughg December 2020.

Data were drawn from a prospectively collected melanoma database and electronic health records, including baseline demographics, disease characteristics, and serum S100b levels at diagnosis and at the follow-up. All participants gave their written informed consent. Furthermore, the study complied with the ethical standards of the Declaration of Helsinki.

Patients with primary cutaneous melanoma stages IA to IIID, as categorized by the 8th edition of the American Joint Committee on Cancer (AJCC) classification were included. Sentinel Lymph Node Biopsy (SLNB) was performed following the National Comprehensive Cancer Network (NCCN) clinical practice guidelines.

Serum S100b concentrations were periodically measured according to hospital protocol (Annex 1), although the retrospective nature of the study allowed for some variations in the timing of these measurements. The primary endpoint was the utility of increased S100b serum levels in diagnosing melanoma metastases categorized by different detection methods including physician suspicion, patient awareness, imaging, and S100b level changes.

Statistical analysis: IBM SPSS Statistics version 26 and p-values < 0.05 were considered statistically significant.

Results

The cohort consisted of 226 patients with invasive cutaneous melanoma **(Table 1).** The median age was 64.3 years (approximately 51.3% of the patients were women). The most common subtype was superficial spreading melanoma, primarily located on the trunk. The median Breslow thickness at diagnosis was 2.7 mm. Initial staging sat at 48.9% (stage I), 34.1% (stage I), and 17% (stage III), with most undergoing surgical treatment only.

During the follow-up period, 69 patients developed metastases. The modes of detection included imaging modalities, clinical examination, patient self-examination, and S100b level changes (**Table 2**). The utility of S100b in actually prompting further diagnostic investigation was limited, often corroborating findings from other methods rather than serving as the primary diagnostic tool (**Table 2**).

Descriptive statistics, confidence intervals, and a classification table for diagnostic categories (true positive, true negative, false positive, false negative) are shown in **table 2**. Sensitivity and specificity rates of S100b were calculated, along with predictive values (**Table 2**). The positive likelihood ratio was used to assess the diagnostic efficiency of S100b elevation **(Table 2)**. Statistical significance was considered for p-values < 0.05.

Discussion

National and international clinical practice guidelines recommend routine S100b assessment especially for high-risk melanoma patients. [4,6,9] Some studies suggest that high baseline or increasing S100b levels at the follow-up are associated with higher risk of disease progression and worse prognosis, warranting further evaluation.[2,3,10] In clinical practice, Podlipnk et al.[3] found that monthly changes in S100b contributed to diagnosing recurrence and supported intensive follow-up for melanoma stages IIB, IIC,

and III. They concluded that monthly increases in S100b values within the normal range enhance the test sensitivity and specificity rates.[3] Peric et al., reported serum S100b increase as the sole sign of disease progression in 20% of the patients.[10] In our cohort, 4.4% of all diagnoses of progression were exclusively based on the increase of S100b (probably due to the inclusion of low-risk melanomas).

The sensitivity and specificity rates of our cohort (43% and 84%) are similar to previously reported values (29% up to 43% and 93% up to 94%), [2,10] The variability in S100b effectiveness may be attributed to the inclusion of early-stage melanomas, which are less likely to reveal significant changes in S100b levels.

Study limitations include small cohort size and single-center data. The strengths are that this study underscores the need to interpret S100b increase alongside rather than relying solely on an absolute cut-off value or rate of change applicable to all cohorts. (supplementary data)

Conclusions

The utility of S100b in the follow-up of patients with non-metastatic melanoma is of limited individual value in the detection of metastases. The supplementary use of imaging modalities and medical examination may add diagnostic value for patient management.

Ética de la publicación

1. ¿Su trabajo ha comportado experimentación en animales?:

No

2. ¿En su trabajo intervienen pacientes o sujetos humanos?:

Sí

Si la respuesta es afirmativa, por favor, mencione el comité ético que aprobó la

investigación y el número de registro.:

COMITÉ DE ÉTICA DE INVESTIGACIÓN CON MEDICAMENTOS DEL HOSPITAL

UNIVERSITARIO DE LA PRINCESA, MADRID

Si la respuesta es afirmativa, por favor, confirme que los autores han cumplido las

normas éticas relevantes para la publicación. :

Sí

Si la respuesta es afirmativa, por favor, confirme que los autores cuentan con el

consentimiento informado de los pacientes. :

Sí

3. ¿Su trabajo incluye un ensayo clínico?:

No

4. ¿Todos los datos mostrados en las figuras y tablas incluidas en el manuscrito se

recogen en el apartado de resultados y las conclusiones?:

Sí

REFERENCES

1. Guy GP Jr, Thomas CC, Thompson T, et al. Vital signs: melanoma incidence and mortality trends and projections - United States*, 1982-2030. MMWR Morb Mortal Wkly Rep*. 2015;64(21):591-96.
2. Deckers EA, Wevers KP, Muller Kobold AC, et al. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. *J Surg Oncol*. 2019;120(6):1031-7.
3. Podlipnik S, Carrera C, Sánchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on

Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. *J Am Acad Dermatol.* 2016;75(3):156-24.

4. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2019;30(12):1884-901.

5. Ertekin SS, Podlipnik S, Ribero S, et al. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients. *J Eur Acad Dermatol Venereol. 2020*;34(7):1482-8.

6. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. *Eur J Cancer.* 2022;170:236-55.

7. Campos-Balea B, Fernández-Calvo O, García-Figueiras R, et al. Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus. *Clin Transl Oncol.* 2022;24(8):1515-23.

8. Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. *J Dtsch Dermatol Ges*. 2016;14(2):158-64.

9. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. *J Clin Oncol*. 2009;27(1):38-44.

10. Peric B, Zagar I, Novakovic S, Zgajnar J, Hocevar M. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. *BMC Cancer*. 2011;11:328.

LEGENDS

Table 1. Baseline characteristics of the cohort.

Table 2. Statistical parameters of the predictive capacity of S100b serum levels.

Table 1: Baseline characteristics of the cohort.

Variable	Category	N	%
Gender	M	110	48.7%
	F	116	51.3%
Melanoma subtype	Amelanotic melanoma	3	1.3%
	Desmoplastic melanoma	5	2.2%
	ALM	11	4.9%
	LMM	10	4.4%
	Nevoid melanoma	5	2.2%
	NM	55	24.3%
	Spitzoid melanoma	7	3.1%

	SSM	119	52.7%
	Unknown	11	4.9%
Melanoma location	Extremity	76	33.8%
	Head and neck	30	13.3%
	Palms or soles	12	5.3%
	Subungueal	3	1.3%
	Trunk	96	42.7%
	Unknown	8	3.6%
Mitosis (0=No, ≥1=Yes)	No	152	73.1%
	Yes	56	26.9%
Ulceration	No	172	79.3%
	Yes	45	20.7%
Staging (8th ed. AJCC)	IA	61	27.9%
	IB	48	21.0%
	IIA	43	19.2%
	IIB	24	10.5%
	IIC	11	4.4%
	IIIA	9	4.1%
	IIIB	8	3.7%
	IIIC	11	6.4%
	IIID	7	2.8%
Treatment	Immunotherapy	1	0.4%
	SM	166	73.8%
	SM + immunotherapy	56	24.9%
	SM + radiotherapy	2	0.9%
SLNB	Performed -	90	39.8%
	Performed +	31	13.7%
	Not Performed	105	46.5%
Lymphadenectomy	Performed -	22	9.7%
	Performed +	10	4.4%
	Not Performed	194	85.8%
Transit metastasis at the follow-up	No	209	92.9%
	Yes	16	7.1%
LN metastasis at the follow-up	No	197	87.2%
	Yes	29	12.8%
Visceral metastases at the follow-up	No	202	89.3%
	Yes	24	10.7%
Detection of LN or visceral metastases	Doctor	12	17.8%
	Image	37	53.3%
	Patient	17	24.5%
	S100b	3	4.4%
Renal or hepatic failure	CHF	5	41.7%

	CRF	7	58.3%
Case classification	TRUE POSITIVE	19	8.4%
	TRUE NEGATIVE	152	67.6%
	FALSE POSITIVE	29	12.9%
	FALSE NEGATIVE	25	11.1%
Follow-up adherence*	Bad	21	9.3%
	Good	205	90.7%
Age		226	64.3 (Mean) 15.2 (SD)
Breslow thickness (mm)		199	2.7 (Mean) 3.4 (SD)

*ALM: Acral lentiginous melanoma, CHF: Chronic hepatic failure, CRF: Chronic renal failure, F: Female, LMM: Lentigo maligna melanoma, LN: lymph nodes; M: Male, NM: Nodular melanoma, SLNM: Sentinel lymph node biopsy, SM: surgical margin, SSM: Superficial spreading melanoma- *Good follow up is defined as having accomplished >75% of the S100b determinations ordered by the physician according to the follow-up regimen based on the stage.*

Table 2. Statistical parameters of the predictive capabilities of S100b serum levels

		Relapse		Se (%)	Sp (%)	PPV (%))	NPV (%)	LR (+)
		Yes	No					
S100 > 0.15ug/L	Yes	19	29	43	84	40	86	2.7
	No	25	152					

LR: Likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp: specificity. Wilson score interval was performed. A classification table was created for the 4 possible categories (true positive, true negative, false positive, false negative). Evaluation was determined by sensitivity (Se), specificity (Sp) and predictive values: negative (PNV) and positive (PPV) and their 95% confidence intervals (95%CI) using the Wilson score interval. Additionally, we calculated the likelihood ratio for positive (LR+) defined as sensitivity/(1-specificity), which shows the number of true positives for each false positive.

Annex 1. Follow-up timeline according to Malignant Melanoma stage.

Stage	Physical Examination and Consultation	Laboratory Analysis*	Regional Lymph Node Ultrasound	Total Body CT PET-CT	CNS MRI
In situ MM (0, IA)	-12 months -6 months (if multiple nevi and/or personal/family history of melanoma)	-12 months -6 months (if multiple nevi and/or personal/family history of melanoma)	-	-	-
IB	-6 months for 5 years -12 months subsequently	-6 months for 5 years -12 months subsequently	-12 months	-	-
IIA-B	-6 months for 5 years -12 months subsequently	-6 months for 5 years -12 months subsequently	-6 months for 5 years	-	-
IIC-IIIA	-6 months for 5 years -12 months subsequently	-6 months for 5 years -12 months subsequently	-6 months for 5 years	-	-
IIIB-C	-3 months for 2 years -6 months for 5 years -12 months subsequently	-3 months for 2 years -6 months for 5 years -12 months subsequently	-6 months for 5 years	-6 months for 5 years	According to clinical examination
IV	-3 months for 2 years -6 months for 5 years -12 months subsequently	-3 months for 2 years -6 months for 5 years -12 months subsequently	According to clinical examination	-3 months for 1 year -6 months for 2-5 years -12 months subsequently	According to clinical examination

Legend: -: No; T: Tumour; CT: Computed Tomography; PET: Positron Emission Tomography; MRI: Magnetic Resonance Imaging; CNS: Central Nervous System.
*including: LDH and S100b protein